<DOC>
	<DOCNO>NCT02302508</DOCNO>
	<brief_summary>Clopidogrel efficacy appear diminished patient type 2 diabetes ( T2D ) continue show increase risk adverse cardiovascular event mortality compare without T2D.The aim first project describe pharmacokinetic ( PK ) profile three antiplatelet drug 4 group patient accord diabetic non-diabetic status . To end , PK profile determine single oral dose 300 mg clopidogrel , 60 mg prasugrel 180 mg ticagrelor patient ( n=108 ) ; 1 ) T2D good glycemic control ; 2 ) T2D poor glycemic control ; 3 ) insulin-treated diabetes ; 4 ) non-diabetic subject .</brief_summary>
	<brief_title>Pharmacokinetics Antiplatelet Drugs Diabetic pAtients</brief_title>
	<detailed_description>Clopidogrel efficacy appear diminished patient T2D continue show increase risk adverse cardiovascular event mortality compare without T2D . To contrary , response prasugrel ticagrelor appear conserved ACS patient diabetes . There several mechanism may contribute blunt response clopidogrel postulate decreased concentration clopidogrel active metabolite worth pursue . The overall objective proposal describe pharmacokinetic profile three antiplatelet drug namely , clopidogrel , prasugrel ticagrelor four group patient accord diabetic non-diabetic status . Patients ( n=108 ) recruit constitute 4 group : Group I , 27 confirm T2D A1C ≤7 ; Group II , 27 patient poor glycemic control A1C Patients ( n=108 ) recruit constitute 4 group : Group I , 27 confirm T2D A1C &lt; 7.0 ; Group II , 27 patient poor glycemic control A1C &gt; 7.5 ; Group III , 27 patient insulin-treated T2D ; Group IV , 27 sex-matched non-diabetic healthy subject . Subjects type 2 diabetes accord Canadian Clinical Guidelines recruit CHUM outpatient clinic . After overnight fast , participant admit CRCHUM 's Clinical Research Unit ( hospitalize ) . A crossover randomize study design 3 phase ( washout period 12 day phase ) conduct . Subjects receive single oral dose clopidogrel 300 mg prasugrel 60 mg ticagrelor 180 mg randomize fashion 3 different occasion . Serial blood sample draw urine collect 10 hour ( PK PD analysis ) . A blood sample take pharmacogenetic analysis . Additional blood sample collect administration antiplatelet drug measure fast insulin , glycaemia level determine HOMA-IR . In addition , follow covariates namely , gender , age , weight , duration diabetes drug profile also record . Their regular medication administer 4 hour administration antiplatelet drug .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Platelet Aggregation Inhibitors</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Participants ≥18 year old Nonsmokers ( &gt; 3 month ) T2D good glycemic control A1C &lt; 7.0 T2D poor glycemic control A1C &gt; 7.5 Insulintreated T2D Nondiabetic healthy subject Subjects estimate glomerular filtration ( MDRD ) &lt; 50 mL/min/1.73m2 ALT AST 3 time upper limit normal Organ transplant recipient Inflammatory illness ( i.e. , polyarthritis , hepatitis , cirrhosis , active infectious disease ) Active cancer ( except nonmelanoma skin cancer ) Uncontrolled thyroid function Inflammatory bowel disease ( ulcerous colitis Crohn 's disease ) , bariatric surgery Pregnancy History drug alcohol abuse Platelet function disorder , One follow therapy : P2Y12 inhibitor , antithrombotics , antibiotic , anticoagulant , antiviral , CYP450 inducer ( carbamazepine , phenobarbital , phenytoin , rifampin , StJohn 's worth ) , CYP450 inhibitor ( amiodarone , fluoxetine , verapamil ) , immunosuppressor , INFs , grapefruit juice ( &lt; 4 week ) investigational drug Intolerance hypersensitivity antiplatelet drug excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug metabolism</keyword>
	<keyword>platelet reactivity</keyword>
	<keyword>carboxylesterase</keyword>
	<keyword>cytochrome p450</keyword>
	<keyword>type 2 diabetes</keyword>
	<keyword>active metabolite</keyword>
</DOC>